{
  "slug": "teva-pharmaceutical-industries",
  "name": "Teva Pharmaceutical Industries",
  "description": "Teva Pharmaceuticals is a leading innovative biopharmaceutical company, enabled by a world-class generics business. Its goal is to provide innovative treatments and quality generic and biosimilar medicines for millions of people globally, with innovation for patients at the heart of its drug development and delivery.",
  "url": "https://optimly.ai/brand/teva-pharmaceutical-industries",
  "websiteUrl": null,
  "logoUrl": "https://logo.clearbit.com/tevausa.com",
  "baiScore": 33,
  "bai_tier_status": "active",
  "bai_score_status": "active",
  "archetype": "Incumbent",
  "archetype_status": "active",
  "category": "Biopharmaceutical",
  "categorySlug": null,
  "keyFacts": [],
  "aiReadiness": [],
  "competitors": [],
  "competitorsProse": null,
  "inboundCompetitors": [],
  "aiAlternatives": [],
  "parentBrand": null,
  "subBrands": [],
  "updatedAt": "2026-08-09T00:02:27.837Z",
  "verifiedVitals": {
    "website": "https://tevausa.com",
    "headquarters": "Not explicitly stated in the provided text.",
    "pricing_model": "Implied competitive pricing for generics and biosimilars, alongside value-based pricing for innovative specialty medications. Exact models are not detailed.",
    "core_products": "Innovative treatments, quality generic medicines, biosimilar medicines. Specific products mentioned include AUSTEDO® (deutetrabenazine) tablets, AUSTEDO XR®, AHZANTIVE® (aflibercept) biosimilar, Ecopipam (investigational), Olanzapine Long-Acting Injectable (TEV-‘749).",
    "key_differentiator": "A unique combination of being a leading innovative biopharmaceutical company with a robust, world-class generics business, focused on increasing both the accessibility and affordability of medicines through in-house innovation and strategic partnerships.",
    "target_markets": "Millions of people globally requiring innovative and affordable pharmaceutical solutions, including those with neurological disorders (Tourette Syndrome, Tardive Dyskinesia, Huntington's Disease), schizophrenia, and eye conditions.",
    "funding_stage": "Publicly Traded (implied by 'Investors' section and Q2 financial results announcements).",
    "subcategory": "Generics, Innovative Medicines, Biosimilars"
  },
  "intentTags": {
    "problemIntents": [
      "Lifestyle & Dietary Interventions: For some health conditions, patients might seek to manage symptoms or progression through non-pharmacological means such as specific diets, exercise regimens, or alt",
      "Untreated Conditions: In some cases, individuals may choose not to pursue medical treatment for their conditions, which can lead to continued symptoms, disease progression, or impact on quality of lif"
    ],
    "solutionIntents": [
      "Teva Pharmaceuticals",
      "Teva generics",
      "Teva R&D pipeline",
      "Other Pharmaceutical Brands: Patients and healthcare providers have the option to choose generic or branded medications from other pharmaceutical companies that offer treatments for similar conditions"
    ],
    "evaluationIntents": []
  },
  "timestamp": 1786399009790
}